As an ideal nanovector candidate, microvesicles (MVs) have been gradually utilized for packaging kinds of functional molecules for effective tumor diagnosis and therapy; however, the deficiency of their tumor targeting influenced their therapy efficacy. Through a facile phospholipid substitution strategy, MVs-based drug delivery system (DDS) was apparently endowed with high tumor targeting toward breast cancer thanks to the modified folate onto the membrane of MVs, simultaneously possessing a synergistic antitumor effect, and in vivo tumor imaging attributed to the SA-QDs labeling. Tumor killing effect could be improved up to 15 percentages with the help of the improved tumor targeting ability.
Keywords: in vivo imaging; microvesicles; phospholipid substitution; synergistic therapy; tumor targeting.